Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBITDA (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBITDA for 11 consecutive years, with -$92.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 801.49% to -$92.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$130.3 million through Dec 2025, down 68.19% year-over-year, with the annual reading at -$130.3 million for FY2025, 68.19% down from the prior year.
  • EBITDA for Q4 2025 was -$92.6 million at Cartesian Therapeutics, down from -$35.9 million in the prior quarter.
  • The five-year high for EBITDA was $28.7 million in Q1 2022, with the low at -$177.6 million in Q4 2023.
  • Average EBITDA over 5 years is -$20.9 million, with a median of -$10.8 million recorded in 2023.
  • The sharpest move saw EBITDA crashed 3128.85% in 2023, then soared 221.34% in 2024.
  • Over 5 years, EBITDA stood at $12.2 million in 2021, then plummeted by 52.05% to $5.9 million in 2022, then plummeted by 3128.85% to -$177.6 million in 2023, then soared by 94.22% to -$10.3 million in 2024, then tumbled by 801.49% to -$92.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$92.6 million, -$35.9 million, and $15.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.